|
US6402215B1
(en)
*
|
1996-05-21 |
2002-06-11 |
American Moto Products, Inc. |
Vehicle cargo bed extender
|
|
EP2210607B1
(en)
|
2003-09-26 |
2011-08-17 |
Exelixis Inc. |
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
|
|
CA2572331A1
(en)
|
2004-07-02 |
2006-02-09 |
Exelixis, Inc. |
C-met modulators and method of use
|
|
WO2006108059A1
(en)
|
2005-04-06 |
2006-10-12 |
Exelixis, Inc. |
C-met modulators and methods of use
|
|
WO2008076415A1
(en)
|
2006-12-14 |
2008-06-26 |
Exelixis, Inc. |
Methods of using mek inhibitors
|
|
UY31800A
(es)
|
2008-05-05 |
2009-11-10 |
Smithkline Beckman Corp |
Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
|
|
AR075084A1
(es)
|
2008-09-26 |
2011-03-09 |
Smithkline Beecham Corp |
Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
|
|
CA2743416A1
(en)
|
2008-11-13 |
2010-05-20 |
Exelixis Inc. |
Methods of preparing quinoline derivatives
|
|
US20130030172A1
(en)
|
2008-12-04 |
2013-01-31 |
Exelixis, Inc. |
Methods of Preparing Quinoline Derivatives
|
|
TW201920110A
(zh)
|
2009-01-16 |
2019-06-01 |
美商艾克塞里克斯公司 |
包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
|
|
BR112012001118A2
(pt)
|
2009-07-17 |
2016-02-23 |
Exelixis Inc |
formas cristalinas de n-[3-flúor-4-({6-(metilóxi)-7-[(3-morfolin-4-ilpropil)óxi]-quinolin-4-il}óxi)fenil]-n'-(4-fluorfenil)ciclopropano-1,1-dicarboxamida, composição farmacêutica com as mesmas, métodos de preparação das mesmas e tratamento de câncer
|
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
MX2012008898A
(es)
*
|
2010-02-03 |
2012-11-06 |
Incyte Corp |
Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met.
|
|
EA201290906A1
(ru)
|
2010-03-12 |
2013-03-29 |
Экселиксис, Инк. |
Кристаллогидратные формы n-[3-фтор-4-({6-(метилокси)-7-[(3-морфолин-4-илпропил)окси]хинолин-4-ил}окси)фенил]-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида
|
|
US20120070368A1
(en)
|
2010-04-16 |
2012-03-22 |
Exelixis, Inc. |
Methods of Using C-Met Modulators
|
|
EP2593091A1
(en)
|
2010-07-16 |
2013-05-22 |
Exelixis, Inc. |
C-met modulator pharmaceutical compositions
|
|
WO2012009722A1
(en)
|
2010-07-16 |
2012-01-19 |
Exelixis, Inc. |
C-met modulator pharmaceutical compositions
|
|
HUE045810T2
(hu)
|
2010-09-27 |
2020-01-28 |
Exelixis Inc |
MET és VEGF kettõs inhibitorai kasztrációrezisztens prosztatarák és oszteoblasztos csontáttétek kezelésére
|
|
WO2012044577A1
(en)
|
2010-09-27 |
2012-04-05 |
Exelixis, Inc. |
Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
|
|
EP2621482A1
(en)
|
2010-09-27 |
2013-08-07 |
Exelixis, Inc. |
Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
|
|
WO2012064967A2
(en)
*
|
2010-11-10 |
2012-05-18 |
Cedars-Sinai Medical Center |
Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases
|
|
US20130252956A1
(en)
|
2010-11-22 |
2013-09-26 |
Howard Kallender |
Methods of treating cancer
|
|
TW201309650A
(zh)
|
2011-02-10 |
2013-03-01 |
艾克塞里克斯公司 |
製造喹啉化合物之方法及包含該化合物之醫藥組合物
|
|
US20120252840A1
(en)
|
2011-04-04 |
2012-10-04 |
Exelixis, Inc. |
Method of Treating Cancer
|
|
EP2704717A1
(en)
|
2011-05-02 |
2014-03-12 |
Exelixis, Inc. |
Method of treating cancer and bone cancer pain
|
|
TW201306842A
(zh)
|
2011-06-15 |
2013-02-16 |
Exelixis Inc |
使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
|
|
GEP201606523B
(en)
|
2011-09-22 |
2016-08-10 |
Exelixis Inc |
Method for treating osteoporosis
|
|
PL2768796T3
(pl)
|
2011-10-20 |
2020-05-18 |
Exelixis, Inc. |
Sposób wytwarzania pochodnych chinoliny
|
|
MX2014005458A
(es)
|
2011-11-08 |
2015-04-16 |
Exelixis Inc |
Inhibidor doble de met y del factor de crecimiento endotelial vascular (vegf) para el tratamiento del cáncer.
|
|
CA2863986A1
(en)
*
|
2012-02-06 |
2013-08-15 |
The Regents Of The University Of California |
Emp2 regulates angiogenesis in cancer cells through induction of vegf
|
|
CN103304552B
(zh)
*
|
2012-03-09 |
2016-12-28 |
广东东阳光药业有限公司 |
取代的吡啶化合物及其使用方法和用途
|
|
HK1207587A1
(en)
|
2012-05-02 |
2016-02-05 |
Exelixis, Inc. |
A dual met - vegf modulator for treating osteolytic bone metastases
|
|
JP6513567B2
(ja)
|
2012-09-07 |
2019-05-15 |
エクセリクシス， インク． |
肺腺癌の治療で使用するためのｍｅｔ、ｖｅｇｆｒ、およびｒｅｔの阻害剤
|
|
US20140221372A1
(en)
|
2013-02-06 |
2014-08-07 |
GlaxoSmithKline Intellectual Property (NO 2.) Limited |
Method of administration and treatment
|
|
GEP20196995B
(en)
|
2013-03-15 |
2019-07-25 |
Inc Exelixis |
Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
|
|
ES2927651T3
(es)
|
2013-04-04 |
2022-11-10 |
Exelixis Inc |
Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
|
|
EP2983639A1
(en)
|
2013-04-04 |
2016-02-17 |
Exelixis, Inc. |
Drug combinations to treat cancer
|
|
EA032757B1
(ru)
|
2014-02-14 |
2019-07-31 |
Экселиксис, Инк. |
Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения
|
|
CN106255499A
(zh)
|
2014-03-17 |
2016-12-21 |
埃克塞里艾克西斯公司 |
卡博替尼制剂的给药
|
|
JP6696908B2
(ja)
|
2014-04-25 |
2020-05-20 |
エグゼリクシス， インコーポレイテッド |
肺腺癌の治療方法
|
|
EA033834B1
(ru)
|
2014-07-31 |
2019-11-29 |
Exelixis Inc |
Способ получения кабозантиниба, меченного фтором-18, и его аналогов
|
|
MA40457A
(fr)
|
2014-08-05 |
2017-06-14 |
Exelixis Inc |
Combinaison de médicaments pour traiter le myélome multiple
|
|
WO2016061253A1
(en)
|
2014-10-14 |
2016-04-21 |
Exelixis, Inc. |
Drug combination to treat melanoma
|